Indication
As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Medicine details

Medicine name:
osimertinib (Tagrisso)
SMC ID:
SMC2171
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
03 June 2019